Pathologic diagnosis of lung cancer - recent developments.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
pubmed:
17
11
2023
medline:
17
11
2023
entrez:
17
11
2023
Statut:
ppublish
Résumé
Diagnosis of lung cancer has previously been based on the evaluation of resection specimen. However, approximately 80% of lung cancers are diagnosed in stage IV. Targeted therapy has changed the practice of pathology. Diagnosis is usually based on small biopsies or even needle aspirations. Subtyping is important, as a molecular classification has to be added. Molecular analysis has to be done in adenocarcinomas and on some of the rarer carcinoma types. Molecular analysis of squamous cell carcinomas should be done in never or former smokers, as they might present with targetable oncogenes. The same applies for adenosquamous carcinomas. Both high-grade neuroendocrine carcinomas should be subtyped. These subtypes might become relevant for new treatment options, currently investigated. Subtyping is done by immunohistochemistry with antibodies for ASCL1, NeuroD1, and POU2F3. In carcinoids, molecular investigation can better define cases with a higher risk of recurrence and metastasis. Diagnosis of lung cancer is most often done on small biopsies or cytological preparations. Only a minimal number of tissues or cellular material is used for diagnosis. A considerable portion is reserved for molecular analysis. Molecular investigation is important in adenocarcinomas, but also for other rare tumor types.
Identifiants
pubmed: 37975321
doi: 10.1097/CCO.0000000000001011
pii: 00001622-990000000-00138
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-62Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO Classification of Lung Tumors: impact of advances since 2015. J Thorac Oncol 2022; 17:362–387.
Huang T, McHugh JB, Berry GJ, Myers JL. Primary mammary analogue secretory carcinoma of the lung: a case report. Hum Pathol 2018; 74:109–113.
Ramos J, Mahmud W, Ocampo FA, et al. Primary mammary-analogue secretory carcinoma of the lung: a rare entity with an unusual location. Int J Surg Pathol 2020; 28:775–781.
Popper HH. Lung adenocarcinomas: comparison between mice and men. Methods Mol Biol 2015; 1267:19–43.
Ullmann R, Bongiovanni M, Halbwedl I, et al. Bronchiolar columnar cell dysplasia--genetic analysis of a novel preneoplastic lesion of peripheral lung. Virchows Arch 2003; 442:429–436.
Travis WD, Brambilla E, Burke AP, Marx A. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Geneva: IARC, WHO Press; 2015.
WHO Classification of Tumours Editorial Board. Thoracic tumours. Lyon, France: IARC Publications; 2021.
Moreira AL, Ocampo PSS, Xia Y, et al. A grading system for invasive pulmonary adenocarcinoma: a proposal from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol 2020; 15:1599–1610.
Popper H, Gruber-Mösenbacher U, Pall G, et al. The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of nonsmall cell lung cancer with focus on predictive biomarkers. memo Magazine Eur Med Oncol 2020; 13:11–26.
Castro CY, Ostrowski ML, Barrios R, et al. Relationship between Epstein-Barr virus and lymphoepithelioma-like carcinoma of the lung: a clinicopathologic study of 6 cases and review of the literature. Hum Pathol 2001; 32:863–872.
Tanaka M, Kato K, Gomi K, et al. NUT midline carcinoma: report of 2 cases suggestive of pulmonary origin. Am J Surg Pathol 2012; 36:381–388.
Sholl LM, Nishino M, Pokharel S, et al. Primary pulmonary NUT midline carcinoma: clinical, radiographic, and pathologic characterizations. J Thorac Oncol 2015; 10:951–959.
Le Loarer F, Watson S, Pierron G, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet 2015; 47:1200–1205.
Rekhtman N, Montecalvo J, Chang JC, et al. SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol 2020; 15:231–247.
Herpel E, Rieker RJ, Dienemann H, et al. SMARCA4 and SMARCA2 deficiency in nonsmall cell lung cancer: immunohistochemical survey of 316 consecutive specimens. Ann Diagn Pathol 2017; 26:47–51.
Ullmann R, Petzmann S, Klemen H, et al. The position of pulmonary carcinoids within the spectrum of neuroendocrine tumors of the lung and other tissues. Genes Chromosomes Cancer 2002; 34:78–85.
Brcic L, Heidinger M, Sever AZ, et al. Prognostic value of cyclin A2 and B1 expression in lung carcinoids. Pathology 2019; 51:481–486.
Swarts DR, Scarpa A, Corbo V, et al. MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids. J Clin Endocrinol Metab 2014; 99:E374–E378.
Pelosi G, Sonzogni A, Harari S, et al. Classification of pulmonary neuroendocrine tumors: new insights. Transl Lung Cancer Res 2017; 6:513–529.
Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer 2019; 19:289–297.
Baine MK, Hsieh MS, Lai WV, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol 2020; 15:1823–1835.
Lin CA, Yu SL, Chen HY, et al. EGFR-mutant SCLC exhibits heterogeneous phenotypes and resistance to common antineoplastic drugs. J Thorac Oncol 2019; 14:513–526.
Miyoshi T, Umemura S, Matsumura Y, et al. Genomic profiling of large-cell neuroendocrine carcinoma of the lung. Clin Cancer Res 2017; 23:757–765.
Derks JL, Leblay N, Thunnissen E, et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res 2018; 24:33–42.
Klemen H S-JF, Popper HH. Morphological and immunohistochemical study of typical and atypical carcinoids of the lung, on the bases of 55 cases with clinico-pathological correlation and proposal of a new classification. Endocr Relat Cancer 1994; 1:53–62.
Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in nonsmall-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983–991.
Tsamis I, Chachali SP, Gomatou G, et al. Pulmonary blastoma: a comprehensive overview of a rare entity. Adv Respir Med 2021; 89:511–519.